Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Shire    SHP   JE00B2QKY057

SHIRE (SHP)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 01/19 05:35:18 pm
3461 GBp   +0.25%
01/19 SHIRE PLC SHIRE : Directorate Change
01/19 SHIRE PLC : Directorate change
01/16 SHIRE : Megan Sullivan Joins LTEN Board of Directors
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Shire plc Shire Plc : Block Listing Interim Review -2-

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/24/2017 | 04:16pm CET
Balance of unallotted securities under scheme(s) from 
 previous return:                                                                        769,615 
Plus: The amount by which the block scheme(s) has 
 been increased since the date of the last return (if 
 any increase has been applied for):                                                         Nil 
Less: Number of securities issued/allotted under scheme(s) 
 during period (see LR3.5.7G):                                                           408,873 
Equals: Balance under scheme(s) not yet issued/allotted 
 at end of period:                                                                       360,742 
 
 
 
 
 
 
 
Name of applicant:                                              Shire plc 
                                                                Shire Employee Stock Purchase 
Name of scheme:                                                 Plan 
                                                                November 23, 
Period of return:                     From:                     2016           To:  May 22, 2017 
Balance of unallotted securities under scheme(s) from 
 previous return:                                                                        244,057 
Plus: The amount by which the block scheme(s) has 
 been increased since the date of the last return (if 
 any increase has been applied for):                                                         Nil 
Less: Number of securities issued/allotted under scheme(s) 
 during period (see LR3.5.7G):                                                             6,359 
Equals: Balance under scheme(s) not yet issued/allotted 
 at end of period:                                                                       237,698 
 
 
 
 
Name of applicant:                                              Shire plc 
                                                                Shire Long Term Incentive Plan 
Name of scheme:                                                 2015 
                                                                November 23, 
Period of return:                     From:                     2016          To:  May 22, 2017 
Balance of unallotted securities under scheme(s) from 
 previous return:                                                                      2,836,412 
Plus: The amount by which the block scheme(s) has 
 been increased since the date of the last return (if 
 any increase has been applied for):                                                         Nil 
Less: Number of securities issued/allotted under scheme(s) 
 during period (see LR3.5.7G):                                                           149,340 
Equals: Balance under scheme(s) not yet issued/allotted 
 at end of period:                                                                     2,687,072 
 
 
 
 
Name of applicant:                                              Shire plc 
                                                                Shire Global Employee Stock 
Name of scheme:                                                 Purchase Plan 
                                                                November 23, 
Period of return:                     From:                     2016          To:   May 22, 2017 
Balance of unallotted securities under scheme(s) from 
 previous return:                                                                      1,604,243 
Plus: The amount by which the block scheme(s) has 
 been increased since the date of the last return (if 
 any increase has been applied for):                                                         Nil 
Less: Number of securities issued/allotted under scheme(s) 
 during period (see LR3.5.7G):                                                             3,400 
Equals: Balance under scheme(s) not yet issued/allotted 
 at end of period:                                                                     1,600,843 
 
 
 
 
Name of applicant:                                              Shire plc 
Name of scheme:                                                 Baxalta Exchange Awards 
                                                                November 23, 
Period of return:                     From:                     2016           To:  May 22, 2017 
Balance of unallotted securities under scheme(s) from 
 previous return:                                                                     20,488,204 
Plus: The amount by which the block scheme(s) has 
 been increased since the date of the last return (if 
 any increase has been applied for):                                                         Nil 
Less: Number of securities issued/allotted under scheme(s) 
 during period (see LR3.5.7G):                                                         2,492,337 
Equals: Balance under scheme(s) not yet issued/allotted 
 at end of period:                                                                    17,995,867 
 
 
 
 
Name of contact:               Sarah Rixon, Company Secretarial Assistant 
Telephone number of contact:                                 01256 894000 
 
 
   For further information please contact: 
 
 
 
 
Investor Relations 
Ian Karp             [email protected]         +1 781 482 9018 
Robert Coates        [email protected]      +44 203 549 0874 
Media 
Lisa Adler           [email protected]    +1 617 588 8607 
Katie Joyce          [email protected]        +1 781 482 2779 
 
 
   NOTES TO EDITORS 
 
   About Shire 
 
   Shire is the global leader in serving patients with rare diseases. We 
strive to develop best-in-class therapies across a core of rare disease 
areas including hematology, immunology, genetic diseases, neuroscience, 
and internal medicine with growing therapeutic areas in ophthalmics and 
oncology. Our diversified capabilities enable us to reach patients in 
more than 100 countries who are struggling to live their lives to the 
fullest. 
 
   We feel a strong sense of urgency to address unmet medical needs and 
work tirelessly to improve people's lives with medicines that have a 
meaningful impact on patients and all who support them on their journey. 
 
   www.shire.com 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Shire plc via Globenewswire 
 
 
 
 

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SHIRE
01/19 SHIRE PLC : Change in Directors or Principal Officers, Financial Statements and ..
01/19 SHIRE PLC SHIRE PLC : Directorate Change
01/19 SHIRE PLC : Directorate change
01/16 SHIRE : Megan Sullivan Joins LTEN Board of Directors
01/16 SHIRE : granted EU marketing authorization for ADYNOVI for adults and adolescent..
01/15 SHIRE : 70+ Year Commitment to the Hemophilia Community
01/15 SHIRE : granted EU marketing authorization for ADYNOVI®▼ for adults and..
01/15 SHIRE : granted EU marketing authorization for ADYNOVI®▼ for adults and ad..
01/10 SHIRE : 65-- Carbamazepine
01/09 SHIRE : Xiidra* Approved by Health Canada To Treat the Signs and Symptoms of Dry..
More news
News from SeekingAlpha
01/19 3 THINGS IN BIOTECH YOU SHOULD LEARN : January 18, 2018
01/18 The 1% Dividend Growth Model Portfolio Will Break The Mold And Transform Opin..
01/17 NOVO NORDISK : Don't Spoil The Ablynx Acquisition
01/17 YOUR DAILY PHARMA SCOOP : Eiger Selloff, Novartis' Cosentyx, RXi Outlines Busine..
01/16 FDA launches new program to boost transparency of clinical data used to suppo..